CanBas

Focus: CanBas is a Japan-based biotechnology company focused on small molecule oncology therapeutics, currently in early-to-mid stage clinical development with a concentrated pipeline around CBP501.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CanBas

AI assessmentNot Hiring

No open roles listed right now. Follow CanBas to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CBP501

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT03113188CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Phase 1

Help build intelligence for CanBas

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology focus with multiple Phase 2 programs in CBP501 combinations targeting high-mortality indications (pancreatic cancer, mesothelioma, NSCLC)
Small molecule chemistry-driven approach offers deep technical learning in drug-disease mechanism optimization
Japan-based biotech with potential access to Asian clinical trial networks and regulatory pathways

Watch Out For

No active job openings currently listed; hiring velocity appears minimal or stalled
Pre-revenue stage with unknown funding, cash position, and burn rate creates employment stability uncertainty
No Phase 3 programs and no marketed products means no near-term revenue inflection or IPO catalysts visible

Generated by Claude from CanBas's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CBP501 and Cisplatin

Cancer

Phase 1

Clinical Trials (1)

NCT00551512Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

Phase 1

pemetrexed, cisplatin and CBP501

Malignant Pleural Mesothelioma

Phase 1/2

Clinical Trials (1)

NCT00700336Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Phase 1/2